BioSpace News Archive

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of new senior leaders to create meaningful impact across key growth areas, build for the future, and enhance the patient journey.

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra Foundation and Jiva are collaborating to bring a webinar regarding new approaches for managing COVID-19 cases as cases spike and new variants arise. The webinar-

BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX) , a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem ® Program. The notice of allowance was issued on March 22, 2021 and is related to a new patent application not previously announced.

Industry veteran will draw on unique mix of scientific and business acumen to support Company’s efforts to combat cancer with growing portfolio of novel myeloid-targeting therapies

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (“FDA”) seeking approval

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology.

Walgreens Boots Alliance, Inc. announced financial results for the second quarter of fiscal 2021, which ended Feb. 28, 2021.

Wesana Health Inc., an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness, announced the successful closing of its approximately C$16.1 million oversubscribed private placement through a special purpose financing vehicle ahead of completing its go-public transaction.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2020.

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter ended December 31, 2020, and earlier today reported preliminary topline data. The company will host its quarterly call at 8:00am ET today, with a primary focus on discussing the preliminary top line data.